Bevacizumab for glioblastoma

References

• Committee of Brain Tumor Registry of JapanReport of Brain Tumor Registry of Japan (2001–2004). 13th edNeurol Med Chir2014Suppl 155
   Google Scholar
• StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• BatesDOVascular endothelial growth factors and vascular permeabilityCardiovas Res2010872262271
   PubMed Web of Science ®Google Scholar
• GerstnerERDudaDGdi TomasoEVEGF inhibitors in the treatment of cerebral edema in patients with brain cancerNat Rev Clin Oncol20096422923619333229
   PubMed Web of Science ®Google Scholar
• CohenMHShenYLKeeganPPazdurRFDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiformeOncologist200914111131113819897538
   PubMed Web of Science ®Google Scholar
• TakanoSKimuHTsudaKDecrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumabActa Neurochir Suppl201311818518923564129
   PubMedGoogle Scholar
• ChinotOLWickWMasonWBevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaN Engl J Med2014370870972224552318
   PubMed Web of Science ®Google Scholar
• VredenburghJJCloughesyTSamantMCorticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyOncologist201015121329133421147867
   PubMed Web of Science ®Google Scholar
• NagpalSHarshGRechtLBevacizumab improves quality of life in patients with recurrent glioblastomaChemother Res Pract2011201160281222312554
   PubMedGoogle Scholar
• KaleyTNolanCCarverAOmuroABevacizumab for acute neurologic deterioration in patients with glioblastomaCNS Oncol20132541341825054664
   PubMedGoogle Scholar
• GilbertMRDignamJJArmstrongTSA randomized trial of bevacizumab for newly diagnosed glioblastomaN Engl J Med2014370869970824552317
   PubMed Web of Science ®Google Scholar
• ColmanHZhangLSulmanEPA multigene predictor of outcome in glioblastomaNeuro Oncol2010121495720150367
   PubMed Web of Science ®Google Scholar
• TaphoornMJHenrikssonRBottomleyAHealth-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed GlioblastomaJ Clin Oncol201533192166217526014298
   PubMed Web of Science ®Google Scholar
• WefelJSPughSLArmstrongTSNeurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825J Clin Oncol 2013 ASCO Annual Meeting Abstracts20133115 suppl200423630218
   PubMed Web of Science ®Google Scholar
• ArmstrongTSWonMWefelJSComparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825J Clin Oncol 2013, ASCO Annual Meeting Abstracts20133115 suppl2003
   Web of Science ®Google Scholar
• PhillipsHSKharbandaSChenRMolecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell20069315717316530701
   PubMed Web of Science ®Google Scholar
• SandmannTBourgonRGarciaJPatients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialJ Clin Oncol201533252735274426124478
   PubMed Web of Science ®Google Scholar
• WickWChinotOLMasonWPPatterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB)J Clin Oncol 2014 ASCO Annual Meeting Abstracts20143215 suppl2014:2051
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• ChamberlainMCJohnstonSKSalvage therapy with single agent bevacizumab for recurrent glioblastomaJ Neurooncol201096225926919593660
   PubMed Web of Science ®Google Scholar
• KreislTNZhangWOdiaYA phase II trial of single-agent bevacizumab in patients with recurrent anaplastic gliomaNeuro Oncol201113101143115021865400
   PubMed Web of Science ®Google Scholar
• NaganeMNishikawaRNaritaYPhase II study of single-agent bevacizumab in Japanese patients with recurrent malignant gliomaJpn J Clin Oncol2012421088789522844129
   PubMed Web of Science ®Google Scholar
• KaloshiGBraceGRrojiABevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experienceTumori201399560160324362864
   PubMed Web of Science ®Google Scholar
• NaritaYDrug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumorsJpn J Clin Oncol201343658759523585688
   PubMed Web of Science ®Google Scholar
• WefelJSCloughesyTZazzaliJLNeurocognitive function in patients with recurrent glioblastoma treated with bevacizumabNeuro Oncol201113666066821558074
   PubMed Web of Science ®Google Scholar
• DuerinckJClementPMBouttensFPatient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastomaJ Neurol2015262374275125572162
   PubMed Web of Science ®Google Scholar
• TabouretEBarrieMThiebautALimited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimenJ Neurooncol2013114219119823756726
   PubMed Web of Science ®Google Scholar
• LevinVAMendelssohnNDChanJImpact of bevacizumab administered dose on overall survival of patients with progressive glioblastomaJ Neurooncol2015122114515025575937
   PubMed Web of Science ®Google Scholar
• LorgisVMauraGCoppaGRelation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohortsJ Neurooncol2012107235135822076449
   PubMed Web of Science ®Google Scholar
• TaalWOosterkampHMWalenkampAMSingle-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialLancet Oncology201415994395325035291
   PubMed Web of Science ®Google Scholar
• VerhoeffJJLaviniCvan LindeMEBevacizumab and dose-intense temozolomide in recurrent high-grade gliomaAnn Oncol20102181723172720064829
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDACoanABevacizumab and daily temozolomide for recurrent glioblastomaCancer201211851302131221792866
   PubMed Web of Science ®Google Scholar
• RahmanRHempflingKNordenADRetrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumabNeuro Oncol201416111523152924958095
   PubMed Web of Science ®Google Scholar
• LiuZZhangGZhuLRetrospective analysis of bevacizumab in combination with fotemustine in Cinese patients with recurrent glioblastoma multiformeBioMed Res Inter20152015723612
   PubMed Web of Science ®Google Scholar
• SoffiettiRTrevisanEBerteroLBevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)J Neurooncol2014116353354124293233
   PubMed Web of Science ®Google Scholar
• ZhangGHuangSWangZA meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiformeJ Clin Neurosci201219121636164023047061
   PubMed Web of Science ®Google Scholar
• FieldKMSimesJNowakAKRandomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaNeuro Oncol201517111504151326130744
   PubMed Web of Science ®Google Scholar
• KaloshiGDiamandiPCakaniBBraceGRrojiAPetrelaMThe added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomasTumori20151011414525702676
   PubMed Web of Science ®Google Scholar
• ReardonDADesjardinsAPetersKBPhase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastomaJ Neurooncol2012107115516421986722
   PubMed Web of Science ®Google Scholar
• LevinVABidautLHouPRandomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous systemInt J Radiat Oncol Biol Phys20117951487149520399573
   PubMed Web of Science ®Google Scholar
• BackMGzellCEKastelanMGuoLWheelerHRLarge volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade gliomaNeurooncol Pract201521485326034641
   PubMedGoogle Scholar
• MagnusonWIan RobinsHMohindraPHowardSLarge volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumabJ Neurooncol2014117113313924469853
   PubMed Web of Science ®Google Scholar
• FliegerMGanswindtUSchwarzSBRe-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment optionJ Neurooncol2014117233734524504501
   PubMed Web of Science ®Google Scholar
• HundsbergerTBruggeDPutoraPMWederPWeberJPlasswilmLRe-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomasJ Neurooncol2013112113313923314822
   PubMed Web of Science ®Google Scholar
• StuppRWongETKannerAANovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityEur J Cancer201248142192220222608262
   PubMed Web of Science ®Google Scholar
• HamzaMAMandelJJConradCASurvival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastomaJ Neurooncol2014119113514024803001
   PubMed Web of Science ®Google Scholar
• PiccioniDELaiADeferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyNeuro Oncol201416101427142825155359
   PubMed Web of Science ®Google Scholar
• ZunigaRMTorcuatorRJainRRebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade gliomaJ Neurooncol201099223724220151176
   PubMed Web of Science ®Google Scholar
• CohnALBekaii-SaabTBendellJCClinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP)J Clin Oncol 2010 ASCO Annual Meeting Proceedings20101815 suppl3596
   Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol200826335326533418854571
   PubMed Web of Science ®Google Scholar
• ReardonDAHerndonJE2ndPetersKBBevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsBr J Cancer201210791481148723037712
   PubMed Web of Science ®Google Scholar
• HoveyEJFieldKMRosenthalMAContinuing or ceasing bevacizumab at disease progression: results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastomaJ Clin Oncol 2013 ASCO Annual Meeting Abstracts20153315 suppl2015:2003
   Web of Science ®Google Scholar
• FraumTJKreislTNSulJFineHAIwamotoFMIschemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapyJ Neurooncol2011105228128921603965
   PubMed Web of Science ®Google Scholar
• KhasrawMHolodnyAGoldlustSADeAngelisLMIntracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experienceAnn Oncol201223245846321543627
   PubMed Web of Science ®Google Scholar
• PerryJRThromboembolic disease in patients with high-grade gliomaNeuro Oncol201214Suppl 4iv73iv8023095833
   PubMedGoogle Scholar
• NalluriSRChuDKeresztesRRisk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisJAMA2008300192277228519017914
   PubMed Web of Science ®Google Scholar
• NghiemphuPLGreenRMPopeWBLaiACloughesyTFSafety of anticoagulation use and bevacizumab in patients with gliomaNeuro Oncol200810335536018436627
   PubMed Web of Science ®Google Scholar
• NordenADBartolomeoJTanakaSSafety of concurrent bevacizumab therapy and anticoagulation in glioma patientsJ Neurooncol2012106112112521706358
   PubMed Web of Science ®Google Scholar
• RanpuraVHapaniSChuangJWuSRisk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trialsActa Oncol201049328729720156114
   PubMed Web of Science ®Google Scholar
• ScappaticciFASkillingsJRHoldenSNArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabJ Natl Cancer Inst200799161232123917686822
   PubMed Web of Science ®Google Scholar
• KreislTNToothakerTKarimiSDeAngelisLMIschemic stroke in patients with primary brain tumorsNeurology200870242314232018541885
   PubMed Web of Science ®Google Scholar
• RanpuraVPulipatiBChuDZhuXWuSIncreased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysisAm J Hypertens201023546046820186127
   PubMed Web of Science ®Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol200920580781519150949
   PubMed Web of Science ®Google Scholar
• ZhongJAliANVoloschinADBevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumabCancer201512191456146225557543
   PubMed Web of Science ®Google Scholar
• WagnerCCHeldUKofmehlRBattegayEZimmerliLHoferSRole of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma – a prospective analysisActa Oncol201453457257524219539
   PubMed Web of Science ®Google Scholar
• MirOCoriatRCabanesLAn observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOncologist20111691325133221807768
   PubMed Web of Science ®Google Scholar
• WickASchaferNDornerNArterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcomeJ Neurooncol201097115715819727565
   PubMed Web of Science ®Google Scholar
• EreminaVJeffersonJAKowalewskaJVEGF inhibition and renal thrombotic microangiopathyN Engl J Med2008358111129113618337603
   PubMed Web of Science ®Google Scholar
• WuSKimCBaerLZhuXBevacizumab increases risk for severe proteinuria in cancer patientsJ Am Soc Nephrol20102181381138920538785
   PubMed Web of Science ®Google Scholar
• ClarkAJButowskiNAChangSMImpact of bevacizumab chemotherapy on craniotomy wound healingJ Neurosurg201111461609161621142749
   PubMed Web of Science ®Google Scholar
• AbramsDAHansonJABrownJMHsuFPDelashawJBJrBotaDATiming of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade gliomaJ Clin Neurosci2015221353925481268
   PubMed Web of Science ®Google Scholar